PetMed Express (PETS) to Release Quarterly Earnings on Monday

PetMed Express (NASDAQ:PETS) is expected to issue its Q4 2026 resultson Monday, May 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $52.00 million for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Monday, June 8, 2026 at 4:00 PM ET.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.44). PetMed Express had a negative net margin of 35.51% and a negative return on equity of 70.81%. The company had revenue of $40.66 million for the quarter, compared to the consensus estimate of $54.04 million. On average, analysts expect PetMed Express to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

PetMed Express Trading Down 1.1%

NASDAQ PETS traded down $0.03 on Monday, reaching $2.28. 26,309 shares of the stock were exchanged, compared to its average volume of 129,662. PetMed Express has a one year low of $1.57 and a one year high of $4.32. The firm has a market capitalization of $48.69 million, a PE ratio of -0.73 and a beta of 0.78. The company’s 50-day simple moving average is $2.44 and its two-hundred day simple moving average is $2.66.

Institutional Investors Weigh In On PetMed Express

A number of large investors have recently modified their holdings of the business. Steel Partners Holdings L.P. acquired a new stake in PetMed Express during the 4th quarter worth about $620,000. Federated Hermes Inc. boosted its holdings in PetMed Express by 30.1% during the fourth quarter. Federated Hermes Inc. now owns 627,743 shares of the company’s stock worth $2,009,000 after buying an additional 145,357 shares in the last quarter. Bridgeway Capital Management LLC grew its position in PetMed Express by 164.3% during the third quarter. Bridgeway Capital Management LLC now owns 107,816 shares of the company’s stock valued at $271,000 after buying an additional 67,016 shares during the period. CIBC Bancorp USA Inc. purchased a new position in PetMed Express in the third quarter valued at $153,000. Finally, UMB Bank n.a. acquired a new position in shares of PetMed Express in the fourth quarter worth about $192,000. Hedge funds and other institutional investors own 73.33% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of PetMed Express to a “hold” rating in a research report on Thursday. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

PetMed Express Company Profile

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non?prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private?label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.